TETs Link Hydrogen Sulfide to Immune Tolerance  by Oh, Soyoung A. & Li, Ming O.
Immunity
PreviewsTETs Link Hydrogen Sulfide to Immune ToleranceSoyoung A. Oh1 and Ming O. Li1,*
1Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
*Correspondence: lim@mskcc.org
http://dx.doi.org/10.1016/j.immuni.2015.08.001
Demethylation of the Foxp3 locus maintains gene expression and Treg cell stability. Yang et al. (2015) show
that the gasotransmitter hydrogen sulfide co-operates with growth factor TGF-b and interleukin-2 to activate
Tet-mediated DNA demethylation of Foxp3 to promote immune tolerance.CD4+CD25+ regulatory T (Treg) cells,
which express the forkhead-box tran-
scription factor Foxp3, are essential for
the maintenance of immune tolerance
and homeostasis. The majority of Treg
cells are generated in the thymus (tTreg),
but extrathymic Treg cell development
also occurs via the conversion of conven-
tional CD4+ T cells in peripheral tissues
(pTreg). Regardless of origin, the funda-
mental task of Foxp3-expressing Treg
cells is to suppress a variety of immune
responses (e.g., T helper 1 [Th1], Th2,
and Th17 cells). Thus, in contrast to the
differentiation of distinct effector lympho-
cyte lineages, which is shaped by the
specific nature of the inflammatory insult
or pathogen, Treg cell identity must
be preserved across a broad spectrum
of environmental conditions. In this issue
of Immunity, Yang et al. (2015) show
that signaling by the gasotransmitter
hydrogen sulfide (H2S) regulates Treg
cell hypomethylation, a critical feature of
Treg cell identity, by promoting expres-
sion of the ten-eleven translocation (Tet)
proteins that are involved in active DNA
demethylation (Figure 1).
The establishment and maintenance of
a stable Treg cell lineage requires both
Foxp3 expression and the acquisition of
Treg-cell-specific epigenetic modifica-
tions. Indeed, although Foxp3 is con-
sidered a lineage-defining transcription
factor for Treg cells, numerous studies
indicate that Foxp3 expression alone is
not sufficient for the differentiation and
maintenance of a stable Treg cell pheno-
type (Ohkura et al., 2013). Rather, recent
findings demonstrate that Foxp3 acts in
concert with a Treg-cell-specific epige-
nome, which is characterized by a unique
CpG hypomethylation pattern, to ensure
Treg cell development and identity (Oh-
kura et al., 2012). Included among the
genes that exhibit this Treg-cell-specificpattern of DNA hypomethylation is
Foxp3 itself. In particular, demethylation
of the CNS2 (conserved non-coding
DNA sequence) enhancer region in the
Foxp3 locus is important for heritable
Foxp3 expression and the maintenance
of Treg cell identity (Zheng et al., 2010).
How Treg-cell-specific CpG hypome-
thylation is established and maintained
has started to be unraveled. One of the
key inducers of epigenetic reprogram-
ming of Treg cells is T cell receptor
(TCR) signaling (Ohkura et al., 2012).
However, the mechanisms that control
DNA methylation status downstream of
these signaling events remain an open
question. Studies in thymic Treg cell
precursors suggest that active DNA de-
methylation in response to TCR and
interleukin-2 (IL-2) signaling contributes
to the establishment of the appropriate
epigenetic landscape for Treg cell differ-
entiation (Toker et al., 2013). Key players
in the process of active DNA de-
methylation are the recently discovered
Tet proteins, which can modify 5-methyl-
cytosine (5mC) through iterative oxida-
tion to generate 5-hydroxymethylcytosine
(5hmC), 5-formyl cytosine (5fC), and 5-
carboxylcytosine (5caC) (Wu and Zhang,
2014). This active modification of 5mC
by the Tet enzymes can be followed by
passive (replication-dependent) dilution
of the oxidized methyl groups or active
restoration of the unmodified cytosine by
base excision repair. Notably, Tet1 and
Tet2 binding to the Foxp3 CNS2 region
has been reported in Treg cells (Wang
et al., 2013), suggesting a role for the Tet
proteins in the maintenance of Treg cell
identity.
In the current study, Yang et al. (2015)
further elucidated the processes involved
in Treg-cell-specific epigenetic reprog-
ramming by demonstrating that the gaso-
transmitter hydrogen sulfide (H2S) pro-Immunity 43motes Tet-mediated DNA demethylation
to ensure the Treg cell CpG hypo-
methylation signature. Hydrogen sulfide
generation is catalyzed by the enzymes
cystathionine b-synthase (CBS) and cys-
tathionine g-lyase (CSE) using substrates
derived from the metabolism of methio-
nine (Paul and Snyder, 2012). Yang et al.
(2015) found that bulk CD4+ T cells, and
also purified Treg cells, produceH2S, indi-
cating that the enzymatic pathway that
generates the gasotransmitter is present
in these cells. Indeed, thymic and peri-
pheral lymphoid organ CD4+ T cells ex-
pressed CBS and CSE protein, and anal-
ysis of mRNA expression indicated that
both thymically derived and peripherally
induced Treg cells expressed higher
amounts of CBS and CSE than other
CD4+ T cell subsets. Chemical inhibition
of CBS and CSE activity in mice led to a
decrease in Foxp3-expressing Treg cells,
suggesting a role for these enzymes in
maintenance of the Treg cell population.
In line with the results of the inhibitor ex-
periments, Yang et al. (2015) found that
CBS-deficient mice possessed fewer
Treg cells. The loss of Treg cells in CBS-
deficient mice was accompanied by
early lethality, autoantibody production,
and immune cell infiltration into various
tissues. Although CBS-deficient mice
suffered from complications associated
with homocysteinemia (Paul and Snyder,
2012), Yang et al. (2015) demonstrated
that the provision of either exogeneous
Treg cells or an H2S donor (which in-
creases the endogenous Treg cell popu-
lation) ameliorated the disease pheno-
type, indicating that an aberrant immune
response at least partially contributes to
the phenotype observed in CBS-deficient
animals.
Mixed bone marrow chimera experi-
ments indicated a cell-intrinsic role for
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Figure 1. Hydrogen Sulfide Signaling Regulates Hypomethylation of the Treg Cell
Epigenome
The enzymes cystathionine b-synthase (CBS) and cystathionine g-lyase (CSE) generate hydrogen sulfide
(H2S) using substrates derived from the metabolism of methionine. H2S signaling leads to sulfhydration of
the transcriptional activator NFYB, resulting in increased transcription of the Tet genes, which encode the
ten-eleven translocation (Tet) proteins that mediate active DNA methylation through oxidation of 5-meth-
ylcytosine. Tet1 and Tet2 proteins bind to regulatory sites in the Foxp3 locus and promote hypomethyla-
tion of the promoter and CNS2 regions, thereby ensuring Foxp3 expression and stability of the Treg cell
lineage.
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mice appears to result in part from the
altered methylation status of the regulato-
ry regions that control Foxp3 expression.
Unlike wild-type Treg cells, CBS-deficient
Treg cells did not exhibit hypomethylation
of the Foxp3 promoter and CNS2 region.
Loss of the hypomethylation phenotype
in CBS-deficient Treg cells was associ-
atedwith decreasedmessage and protein
of the Tet1 and Tet2 enzymes. In accor-
dance with reduced Tet protein in CBS-
deficient Treg cells, Yang et al. (2015)
demonstrated a loss of 5hmC enrichment
in multiple Foxp3 regulatory regions,
including the promoter and CNS2. Corre-
spondingly, these sites are enriched for
5mC, reflecting the loss of Tet-mediated
conversion of 5mC to 5hmC.
Tet-mediated DNA demethylation can
be controlled through the transcriptional212 Immunity 43, August 18, 2015 ª2015 Elsregulation of the Tet genes (Wu and
Zhang, 2014), and Yang et al. (2015) found
that CBS-deficient CD4+ T cells exhibited
reduced binding of the transcriptional
activator NFYB to the Tet1 and Tet2
promoters. However, provision of a H2S
donor to CBS-deficient mice largely
rescued NFYB binding to both promoter
regions. One mechanism of H2S signaling
is through the sulfhydration of cysteines
on target proteins, which can lead to
enhanced protein function (Paul and
Snyder, 2012). Indeed, H2S appeared to
promote NFYB activity by sulfhydration
of the transcription factor, as shown by
the fact that CBS-deficient CD4+ T cells
that are chemically treated to reduce
protein sulfhydration exhibit decreased
NFYB binding to the Tet1 and Tet2 pro-
moters despite the provision of a H2S
donor. Using liquid chromatography andevier Inc.mass spectrometry techniques, Yang
et al. (2015) identified the modified
cysteine in NFYB and generate an NFYB
mutant that lacks the sulfhydration site.
The mutant NFYB does not exhibit
enhanced binding to the Tet1 and Tet2
promoters upon treatment with a H2S
donor.
Yang et al. (2015) more precisely
address the role of the Tet proteins in
the regulation of Treg cell identity by using
a genetic model of global Tet1 and T-cell-
specific Tet2 deficiency. Similar to the
observations in CBS-deficient mice, Tet
double knockout mice exhibit a reduced
Treg cell population, tissue infiltration by
immune cells, and autoantibody produc-
tion. As was observed for CBS, bone
marrow chimera experiments indicate
that the Tet proteins have a cell-intrinsic
role in the regulation of Treg cell identity.
Tet1- and Tet2-deficient Treg cells ex-
hibited a loss of 5hmC at the Foxp3 regu-
latory regions and exhibited increased
methylation of the promoter and CNS2
regions. In accordance with the model
proposed by the authors, in which H2S
functions by promoting Tet expression,
provision of a H2S donor partially rescued
the Treg cell phenotype in Cbs-deficient,
but not Tet double-deficient, mice.
A key question in the epigenetic control
of cell differentiation is the mechanism by
which DNA-modifying enzymes are re-
cruited to the appropriate sites to exert
their functions. Yang et al. (2015) exam-
ined how TGF-b and IL-2, two key cyto-
kines in Treg cell biology, influence Tet
protein activity. In Treg cells, Tet1 and
Tet2 were found to co-immunoprecipitate
with Smad3 and Stat5, and these interac-
tions were inhibited upon treatment of
Treg cells with TGF-b and IL-2 blocking
antibodies. In addition, blockade of TGF-
b and IL-2 signaling in Treg cells resulted
in diminished Tet1 and Tet2 binding
to regulatory regions in the Foxp3 locus,
whereas TGF-b and IL-2 treatment
of conventional CD4+ T cells led to
increased Tet1 and Tet2 binding to
the same regulatory sites. Furthermore,
siRNA-mediated knockdown of the Tet
proteins, or the combination of Smad3
and Stat5, in conventional CD4+ T cells
inhibits demethylation of the Foxp3
promoter and CNS2 region during peri-
pheral Treg cell conversion, indicating
that TGF-b and IL-2 signaling are in-
volved in regulation of the Treg cell
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tial role for Stat5 in guiding Tet binding
to the Foxp3 locus is of particular interest
given recent findings demonstrating that
IL-2 sensing and Stat5 interactions with
the CNS2 region are important for the
maintenance of Treg cell identity (Feng
et al., 2014).
Acquisition of the proper epigenetic
modifications is critical for the establish-
ment of a stable Treg cell lineage, and
elucidating the signals and molecular
mechanisms that regulate the Treg cell
epigenome are of fundamental impor-
tance. The findings reported by Yang
et al. (2015) provide novel insight into
how signaling by the gasotransmitter
H2S influences DNA demethylation of
key Foxp3 regulatory regions. The pro-
duction of H2S requires substrates gener-ated by the metabolism of methionine,
indicating a role for nutrient sensing in
regulating the Treg cell epigenome. In
the context of previous work in the field,
these findings indicate that the integration
of environmental signals (antigen, cyto-
kine, and nutrients) allows for the dynamic
regulation of Treg cell identity. Indeed,
the tunable nature of these signals might
allow for more precise regulation of Treg
cell identity and function.
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Inhibition of the inflammasome might be beneficial for numerous inflammatory pathologies. In this issue
of Immunity, de Almeida et al. (2015) report that the PYRIN domain-only protein (POP1) efficiently inhibits
inflammasome activation, identifying it as a pan-inflammasome inhibitor.In recent years the inflammasome and
interleukin 1 (IL-1) signaling have been
centrally implicated in many human pa-
thologies. This includes a wide range
of chronic inflammatory disorders such
as diabetes, atherosclerosis, rheumatoid
arthritis, and obesity, among others
(Guo et al., 2015). In addition to these
multifactorial chronic disorders, cryopyri-
nopathies (Cryopyrin-associated periodic
syndromes [CAPS]) are the result of
mutations that cause constitutive inflam-
masome activation and unchecked IL-1
signaling (Broderick et al., 2015). This
has led to an explosion of clinical trials
based on inhibiting IL-1-mediated pathol-
ogies, including the use of an IL-1 recep-
tor antagonist (Anakinra/Kineret), an IL-1receptor decoy (Rilanocept), and various
monoclonal antibodies against IL-1b
(Dinarello et al., 2012; Guo et al., 2015).
In addition to these therapeutic modal-
ities, new small molecule inhibitors target-
ing various steps in the inflammasome
pathway have been developedwith prom-
ising results (Guo et al., 2015). Many of
these therapeutics target signaling down-
stream of IL-1, and even those that target
upstream events such as inflammasome
activation generally target only a specific
type of inflammasome rather than all in-
flammasomes (Guo et al., 2015).
The inflammasome is a multi-compo-
nent structure, which, when formed, acti-
vates caspase-1, which in turn can cleave
the inactive precursors of specific pro-inflammatory cytokines (mainly IL-1b and
IL-18), thereby activating them and lead-
ing to their secretion (Guo et al., 2015).
The best studied of the inflammasomes,
and the one targeted by most current
therapeutics, is the nucleotide binding
domain and leucine-rich repeat (NLR)
pyrin domain containing 3 (NLRP3) in-
flammasome, which, not coincidently, is
associated with the largest number of
inflammasome-mediated diseases (Guo
et al., 2015; Man and Kanneganti, 2015).
The NLRP3 inflammasome responds to
many diverse danger signals including,
but not limited to, extracellular ATP, crys-
tals and other insoluble particles, and
bacterial toxins (Guo et al., 2015; Man
and Kanneganti, 2015). Although not, August 18, 2015 ª2015 Elsevier Inc. 213
